arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Pulmonx Corp

LUNG
$2.58 ▼ -0.24 (-8.51%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
9 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pulmonx Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $105.0M
Dividend Yield —
Revenue Growth 8.0% ↘
Op. Margin -59.3% ↗
ROIC -59.5% ↘
FCF / Share $-0.81 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity 0.69
info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$90.50M
↑ +8.0% —
Net Income Profit after all expenses
$-54.00M
↑ +4.2% —
Operating Margin Operating profit as % of sales
-59.3%
↑ +13.9% 4th
FCF / Share Free cash flow per share
$-0.81
↑ +4.3% —
Long-Term Debt Long-term obligations
$37.09M
— -0.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
9
Financial Health ↑
33
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 33 quarters